Inspire Investing LLC Decreases Position in IQVIA Holdings Inc. (NYSE:IQV)

Inspire Investing LLC lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,695 shares of the medical research company’s stock after selling 350 shares during the quarter. Inspire Investing LLC’s holdings in IQVIA were worth $4,430,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in IQV. Raleigh Capital Management Inc. raised its position in IQVIA by 4.5% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,157 shares of the medical research company’s stock worth $268,000 after purchasing an additional 50 shares during the period. Beacon Financial Group increased its position in shares of IQVIA by 3.4% in the fourth quarter. Beacon Financial Group now owns 4,089 shares of the medical research company’s stock valued at $946,000 after acquiring an additional 133 shares during the period. Integrated Advisors Network LLC increased its position in shares of IQVIA by 141.4% in the fourth quarter. Integrated Advisors Network LLC now owns 12,002 shares of the medical research company’s stock valued at $2,777,000 after acquiring an additional 7,030 shares during the period. Centaurus Financial Inc. purchased a new position in shares of IQVIA in the fourth quarter valued at about $169,000. Finally, ICA Group Wealth Management LLC purchased a new position in shares of IQVIA in the fourth quarter valued at about $77,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Evercore ISI decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Robert W. Baird boosted their price objective on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday, September 20th. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Truist Financial boosted their price target on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, UBS Group boosted their price target on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $269.36.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.60% of the company’s stock.

IQVIA Trading Down 0.4 %

NYSE:IQV opened at $229.26 on Friday. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The company’s 50-day simple moving average is $239.16 and its 200 day simple moving average is $231.74. The firm has a market capitalization of $41.79 billion, a P/E ratio of 29.77, a PEG ratio of 2.18 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same quarter in the previous year, the firm posted $2.22 earnings per share. IQVIA’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.